{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:02:13Z","timestamp":1785528133557,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K19485, 19H03522, 23H02778"],"award-info":[{"award-number":["18K19485, 19H03522, 23H02778"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106364h0003"],"award-info":[{"award-number":["17ck0106364h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Personalized neoantigen vaccines can induce antitumor T cell responses, but only 10-20% of selected peptides have induced immune responses in patients, underscoring the limitations of current prediction strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed a clinically annotated dataset from 352 cancer patients who received personalized neoantigen peptide-pulsed dendritic cell vaccines. We focused on 2,317 short peptides derived from single nucleotide variants for which post-vaccination T cell responses were evaluated by IFN-\u03b3 ELISPOT assay. Immunogenic neoantigen peptides were defined as those inducing a \u22652.0-fold increase in IFN-\u03b3 ELISPOT responses after vaccination. We systematically examined peptide intrinsic characteristics and physicochemical properties, as well as predicted scores related to antigen-processing machinery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Immunogenicity was not associated with specific mutation positions or sequence patterns but was significantly correlated with higher hydrophobicity (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a05.2 \u00d7 10\n                      <jats:sup>-4<\/jats:sup>\n                      ). Among several predictive scores, peptides with higher binding affinity to HLA molecules (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0014 for NetMHC3,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.028 for MHCflurry-affinity), higher binding stability (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.043 for NetMHCstab) or better peptide presentation scores (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.012 for mixmhcPred3,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0085 for MHCflurry-presentation) were significantly enriched among immunogenic neoantigen peptides. Composite models integrating peptide physicochemical features, particularly hydrophobicity, with prediction scores improved the area under the receiver operating characteristic curve and balanced accuracy compared with individual tools alone. Together, these findings highlight the multifactorial determinants of neoantigen immunogenicity and support the integration of complementary peptide features to refine neoantigen prioritization for personalized vaccines and T cell-based immunotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1829509","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:42:30Z","timestamp":1780983750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Peng","family":"Zhao","sequence":"first","affiliation":[{"name":"Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN)","place":["Ibaraki, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Effenberger","sequence":"additional","affiliation":[{"name":"Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN)","place":["Ibaraki, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Umebayashi","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Koya","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Tsujimura","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN)","place":["Ibaraki, Osaka, Japan"]},{"name":"Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kiyotani","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN)","place":["Ibaraki, Osaka, Japan"]},{"name":"Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13498","article-title":"Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens","volume":"109","author":"Kiyotani","year":"2018","journal-title":"Cancer Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-021-00950-w","article-title":"Immunogenomics in personalized cancer treatments","volume":"66","author":"Kiyotani","year":"2021","journal-title":"J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010144","article-title":"Advances in neoantigen-based cancer vaccines","volume":"18","author":"Wu","year":"2026","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1778721","article-title":"Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with Malignant ascites","volume":"50","author":"Morisaki","year":"2021","journal-title":"Immunol Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15213","article-title":"Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis","volume":"41","author":"Morisaki","year":"2021","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2021.1973491","article-title":"Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma","volume":"51","author":"Ichimiya","year":"2022","journal-title":"Immunol Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/cancers14102438","article-title":"Lymph nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy","volume":"14","author":"Morisaki","year":"2022","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223331","article-title":"Immunological analysis of hybrid neoantigen peptide encompassing class I\/II neoepitope-pulsed dendritic cell vaccine","volume":"14","author":"Morisaki","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.3390\/cancers16244204","article-title":"Retrospective analysis of HLA class II-restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer","volume":"16","author":"Morisaki","year":"2024","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571182","article-title":"Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study","volume":"16","author":"Oyama","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-325","article-title":"Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads","volume":"15","author":"Bai","year":"2014","journal-title":"BMC Genomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10004-2","article-title":"Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC","volume":"651","author":"Sahin","year":"2026","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(82)90515-0","article-title":"A simple method for displaying the hydropathic character of a protein","volume":"157","author":"Kyte","year":"1982","journal-title":"J Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1092","article-title":"The immune epitope database (IEDB): 2024 update","volume":"53","author":"Vita","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11","volume":"36","author":"Lundegaard","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T-cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Nielsen","year":"2003","journal-title":"Protein Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv639","article-title":"Gapped sequence alignment using artificial neural networks: application to the MHC class I system","volume":"32","author":"Andreatta","year":"2016","journal-title":"Bioinformatics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2020.09.001","article-title":"MHCflurry 2.0: Improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O'Donnell","year":"2020","journal-title":"Cell Syst"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s42256-023-00694-6","article-title":"Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity","volume":"5","author":"Albert","year":"2023","journal-title":"Nat Mach Intell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-010-0441-4","article-title":"NetCTLpan: pan-specific MHC class I pathway epitope predictions","volume":"62","author":"Stranzl","year":"2010","journal-title":"Immunogenetics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01450-8","article-title":"Predicting MHC-I ligands across alleles and species: how far can we go","volume":"17","author":"Tadros","year":"2025","journal-title":"Genome Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"Muller","year":"2023","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/vaccines13080865","article-title":"Accelerating neoantigen discovery: A high-throughput approach to immunogenic target identification","volume":"13","author":"Pfitzer","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141264","article-title":"Solving an MHC allele-specific bias in the reported immunopeptidome","volume":"5","author":"Klatt","year":"2020","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.03.009","article-title":"Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes","volume":"56","author":"Racle","year":"2023","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7918","article-title":"Neoantigen quality, not quantity","volume":"11","author":"McGranahan","year":"2019","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:42:31Z","timestamp":1780983751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1829509"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1829509","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1829509"}}